Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
Public ClinicalTrials.gov record NCT03975387. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Study ASTX295-01 is a first in human Phase 1/2 open-label study of the safety, pharmacokinetics, and preliminary activity of ASTX295 in participants with wild-type TP53 advanced solid tumors. Phase 1 is a dose escalation and dose expansion study design. Sponsor made the strategic decision to not pursue the Phase 2 part of the study.
Study identification
- NCT ID
- NCT03975387
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 106 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 10, 2019
- Primary completion
- Sep 10, 2023
- Completion
- Aug 14, 2024
- Last update posted
- Apr 8, 2025
2019 – 2024
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Comprehensive Cancer Center Site#114 | Duarte | California | 91010 | — |
| Cedars-Sinai Medical Center Site #105 | Los Angeles | California | 90048 | — |
| Hoag Hospital Site#110 | Newport Beach | California | 92663 | — |
| Holden Comprehensive Cancer Center Site#108 | Iowa City | Iowa | 52242 | — |
| University of Michigan Rogel Cancer Center Site#109 | Ann Arbor | Michigan | 48109 | — |
| Regions Cancer Center Site #115 | Saint Paul | Minnesota | 55101 | — |
| Columbia University Irving Medical Center - Herbert Irving Pavilion Site#104 | New York | New York | 10032 | — |
| University of Pennsylvania-Abramson Cancer Center Site#113 | Philadelphia | Pennsylvania | 19104 | — |
| The University of Texas MD Anderson Cancer Center Site #102 | Houston | Texas | 77030 | — |
| NEXT Oncology Site #101 | San Antonio | Texas | 78229 | — |
| Virgnia Cancer Specialists Site #103 | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03975387, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 8, 2025 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03975387 live on ClinicalTrials.gov.